


PRODUCT INFORMATION



UCM-05194 (ammonium salt)

Item No. 41682

Formal Name: benzenedecanoic acid, (1S)-1-(bromomethyl)-2-(phosphonoxy) ethyl ester, monoammonium salt
MF: C₁₉H₂₉BrO₆P • NH₄
FW: 482.4
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

UCM-05194 (ammonium salt) is supplied as a solid. A stock solution may be made by dissolving the UCM-05194 (ammonium salt) in the solvent of choice, which should be purged with an inert gas. UCM-05194 (ammonium salt) is soluble in DMSO and water. UCM-05194 (ammonium salt) is slightly soluble in ethanol.

UCM-05194 (ammonium salt) is slightly soluble in aqueous solutions. To enhance aqueous solubility, dilute the organic solvent solution into aqueous buffers or isotonic saline. If performing biological experiments, ensure the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

Description

UCM-05194 is an agonist of lysophosphatidic acid receptor 1 (LPA₁).¹ It induces calcium mobilization in RH7777 cells expressing LPA₁ (EC₅₀ = 0.24 μM). It is selective for LPA₁ over LPA₂ and LPA₃ at 10 μM and is 10-fold selective over LPA₅ and 50-fold selective over LPA₄, LPA₆, and autotaxin. UCM-05194 (1 μM) induces neurite retraction in, and migration of, B103 rat neuroblastoma cells overexpressing LPA₁. It induces receptor internalization and neuronal desensitization in the same cells when used at a concentration of 1 μM and reduces the firing activity of primary rat neonatal dorsal root ganglia (DRG) neurons with repeated application at 10 μM. UCM-05194 (10 mg/kg) reduces acetic acid-induced writhing and hind paw mechanical hypersensitivity in mice.

Reference

1. González-Gil, I., Zian, D., Vázquez-Villa, H., *et al.* A novel agonist of the type 1 lysophosphatidic acid receptor (LPA₁), UCM-05194, shows efficacy in neuropathic pain amelioration. *J. Med. Chem.* **63**(5), 2372-2390 (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/09/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM